Phase I/II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation Followed by Maintenance Therapy With Lenalidomide and Sirolimus in Patients With High-Risk Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Lenalidomide (Primary) ; Sirolimus (Primary) ; Tacrolimus
- Indications Graft-versus-host disease; Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2017 Planned End Date changed from 1 Jul 2017 to 31 Dec 2017.
- 30 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2017.
- 14 Mar 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017 as reported by ClinicalTrials.gov record.